A compound, or a pharmaceutically acceptable salt thereof, said compound having the structural Formula: or a tautomer thereof having the structural Formula (I'): or pharmaceutically acceptable salt thereof, wherein: R 1 is selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 heteroalkyl, wherein said C 1-4 alkyl, and C 1-4 heteroalkyl are optionally substituted with one or more halogen; R 2 is selected from the group consisting of H, C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 heteroalkyl, wherein said C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 heteroalkyl are optionally substituted with one or more halogen; ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl; m is 0, 1, 2, or 3; each R A (when present) is independently selected from the group consisting of halogen, -CN, -CH 3, -CH 2 CH 3, -CH(CH 3) 2, cyclopropyl, -CH 2 OCH 3, -CF 3, -CHF 2, -CH 2 F, -OCH 3, -O-cyclopropyl, -O-CH 2 -cyclopropyl, -OCF 3, -OCHF 2, and -OCH 2 F; ring B, R B, and n form a moiety selected from the group consisting of: and R B (when present) is selected from the group consisting of fluoro, chloro, bromo, -OH, -CN, -OCH 3, and -OCH 2 -C≡C-CH 3; n is 0 or 1; ring C is selected from the group consisting of cyclopropyl and cyclobutyl; p is 0, 1, or 2; and each R C (when present) is independently selected from the group consisting of: halogen, - OH, -CN, C 1-4 alkyl, and C 1-4 alkoxy, where said C 1-4 alkyl, and C 1-4 alkoxy are each optionally substituted with 1 to 3 fluorine, wherein C 1-4 heteroalkyl denotes a C 1-4 alkyl which is substituted by one or more moiety independently selected from -O-alkyl, -S-alkyl, -S -alkyl, -S 2 -alkyl, -N alkyl and - N(alkyl) 2. R 1 is selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 heteroalkyl, wherein said C 1-4 alkyl, and C 1-4 heteroalkyl are optionally substituted with one or more halogen; R 2 is selected from the group consisting of H, C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 heteroalkyl, wherein said C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 heteroalkyl are optionally substituted with one or more halogen; ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl; m is 0, 1, 2, or 3; each R A (when present) is independently selected from the group consisting of halogen, -CN, -CH 3, -CH 2 CH 3, -CH(CH 3) 2, cyclopropyl, -CH 2 OCH 3, -CF 3, -CHF 2, -CH 2 F, -OCH 3, -O-cyclopropyl, -O-CH 2 -cyclopropyl, -OCF 3, -OCHF 2, and -OCH 2 F; ring B, R B, and n form a moiety selected from the group consisting of: and R B (when present) is selected from the group consisting of fluoro, chloro, bromo, -OH, -CN, -OCH 3, and -OCH 2 -C≡C-CH 3; n is 0 or 1; ring C is selected from the group consisting of cyclopropyl and cyclobutyl; p is 0, 1, or 2; and each R C (when present) is independently selected from the group consisting of: halogen, - OH, -CN, C 1-4 alkyl, and C 1-4 alkoxy, where said C 1-4 alkyl, and C 1-4 alkoxy are each optionally substituted with 1 to 3 fluorine, wherein C 1-4 heteroalkyl denotes a C 1-4 alkyl which is substituted by one or more moiety independently selected from -O-alkyl, -S-alkyl, -S -alkyl, -S 2 -alkyl, -N alkyl and - N(alkyl) 2.